Health Affairs, 25, no. 5 (2006): 1218-1230 doi: 10.1377/hlthaff.25.5.1218 © 2006 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Tunis, S. R. Articles by Pearson, S. D. Search for Related Content PubMed PubMed Citation Articles by Tunis, S. R. Articles by Pearson, S. D. Related Collections Access To Care Insurance Coverage Managed Care - Medicare Medicare Business Of Health Pharmaceuticals Research And Technology Health Spending Consumer Issues Evidence-Based Medicine

Coverage

Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’

In April 2005 the Centers for Medicare and Medicaid Services (CMS) posted on its Web site a draft guidance document describing a new approach to coverage policy called "coverage with evidence development" (CED). CED offered an option for coverage of promising drugs, biologics, devices, diagnostics, and procedures that would not otherwise meet Medicare’s evidentiary standards for being "reasonable and necessary." An updated guidance was posted 12 July 2006, clarifying several key statutory, regulatory, and operational issues. This paper traces the history of this policy approach, explains the rationale behind the policy, and describes the major challenges that will need to be addressed for CED to become an important advance in evidence-based coverage decision making.

                      What's this?

This article has been cited by other articles:

				J. K. Iglehart Health Insurers and Medical-Imaging Policy -- A Work in Progress N. Engl. J. Med., March 5, 2009; 360(10): 1030 - 1037. [Full Text] [PDF]

				M. R. Gillick Controlling Off-Label Medication Use Ann Intern Med, March 3, 2009; 150(5): 344 - 347. [Abstract] [Full Text] [PDF]

				H. C. Sox Evaluating Off-Label Uses of Anticancer Drugs: Time for a Change Ann Intern Med, March 3, 2009; 150(5): 353 - 354. [Full Text] [PDF]

				M. J. Coye, A. Haselkorn, and S. DeMello Remote Patient Management: Technology-Enabled Innovation And Evolving Business Models For Chronic Disease Care Health Aff., January 1, 2009; 28(1): 126 - 135. [Abstract] [Full Text] [PDF]

				B. E. Hillner, B. A. Siegel, A. F. Shields, D. Liu, I. F. Gareen, E. Hunt, and R. E. Coleman Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry J. Nucl. Med., December 1, 2008; 49(12): 1928 - 1935. [Abstract] [Full Text] [PDF]

				M. J. Khoury, A. Berg, R. Coates, J. Evans, S. M. Teutsch, and L. A. Bradley The Evidence Dilemma In Genomic Medicine Health Aff., November 1, 2008; 27(6): 1600 - 1611. [Abstract] [Full Text] [PDF]

				P. J. Neumann, M. S. Kamae, and J. A. Palmer Medicare's National Coverage Decisions For Technologies, 1999-2007 Health Aff., November 1, 2008; 27(6): 1620 - 1631. [Abstract] [Full Text] [PDF]

				K. Chalkidou, J. Lord, A. Fischer, and P. Littlejohns Evidence-Based Decision Making: When Should We Wait For More Information? Health Aff., November 1, 2008; 27(6): 1642 - 1653. [Abstract] [Full Text] [PDF]

				A. M. Garber Is Having More Preapproval Data The Best Way To Assure Drug Safety? Health Aff., September 1, 2008; 27(5): w371 - w373. [Abstract] [Full Text] [PDF]

				K. Chalkidou, T. Walley, A. Culyer, P. Littlejohns, and A. Hoy Evidence-informed evidence-making J Health Serv Res Policy, July 1, 2008; 13(3): 167 - 173. [Abstract] [Full Text] [PDF]

				G. F. Anderson and K. Chalkidou Spending on Medical Care: More Is Better? JAMA, May 28, 2008; 299(20): 2444 - 2445. [Full Text] [PDF]

				P. S. Douglas, M. Budoff, S. Tunis, P. K. Woodard, R. A. Justman, and R. Honigberg A New Era for Cardiovascular Imaging? Implications of the Revoked National Coverage Decision for CT Angiography on Future Imaging Reimbursement. J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 398 - 403. [Full Text] [PDF]

				G. G. Weinmann, Y.-P. Chiang, and S. Sheingold The National Emphysema Treatment Trial (NETT): A Study in Agency Collaboration Proceedings of the ATS, May 1, 2008; 5(4): 381 - 384. [Abstract] [Full Text] [PDF]

				B. E. Hillner, B. A. Siegel, D. Liu, A. F. Shields, I. F. Gareen, L. Hanna, S. H. Stine, and R. E. Coleman Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry J. Clin. Oncol., May 1, 2008; 26(13): 2155 - 2161. [Abstract] [Full Text] [PDF]

				S. S. Dhruva and R. F. Redberg Variations Between Clinical Trial Participants and Medicare Beneficiaries in Evidence Used for Medicare National Coverage Decisions Arch Intern Med, January 28, 2008; 168(2): 136 - 140. [Abstract] [Full Text] [PDF]

				Medicare's Coverage With Evidence Development: A Policy-Making Tool in Evolution J. Oncol. Pract, November 1, 2007; 3(6): 296 - 301. [Full Text] [PDF]

				S. B. Foote and R. J. Town Implementing Evidence-Based Medicine Through Medicare Coverage Decisions Health Aff., November 1, 2007; 26(6): 1634 - 1642. [Abstract] [Full Text] [PDF]

				K. Chalkidou, A. Hoy, and P. Littlejohns Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research J R Soc Med, October 1, 2007; 100(10): 453 - 460. [Full Text] [PDF]

				P. J. Neumann Challenges Ahead For Federal Technology Assessment Health Aff., March 1, 2007; 26(2): w150 - w152. [Abstract] [Full Text] [PDF]

				R. F. Redberg Evidence, Appropriateness, And Technology Assessment In Cardiology: A Case Study Of Computed Tomography Health Aff., January 1, 2007; 26(1): 86 - 95. [Abstract] [Full Text] [PDF]

				P. S. Keenan, P. J. Neumann, and K. A. Phillips Biotechnology And Medicare's New Technology Policy: Lessons From Three Case Studies Health Aff., September 1, 2006; 25(5): 1260 - 1269. [Abstract] [Full Text] [PDF]